Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau121zxn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS	12	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	13	APR 26	PROMT: New display field available
NEWS	14	APR 26	FIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	15	APR 26	LITALERT now available on STN
NEWS	16	APR 27	NLDB: New search and display fields available

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:34:17 ON 29 APR 2004

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'STNGUIDE' ENTERED AT 09:34:23 ON 29 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 23, 2004 (20040423/UP).

=> FIL HOME

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	0.27

FILE 'HOME' ENTERED AT 09:34:27 ON 29 APR 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.48

FILE 'REGISTRY' ENTERED AT 09:34:33 ON 29 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 APR 2004 HIGHEST RN 677274-15-6
DICTIONARY FILE UPDATES: 27 APR 2004 HIGHEST RN 677274-15-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\STNEXP4\QUERIES\10687334.str



```
chain nodes :
19  20  21  22  23  24
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18
ring/chain nodes :
26  27
chain bonds :
2-26  5-19  9-21  10-22  19-20  19-21  22-24  22-23
ring/chain bonds :
26-27
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12  13-14  13-18
14-15  15-16  16-17  17-18
exact/norm bonds :
9-21  19-20  19-21  22-24  22-23  26-27
exact bonds :
2-26  5-19  10-22
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12  13-14  13-18
14-15  15-16  16-17  17-18


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:CLASS
20:CLASS  21:CLASS  22:CLASS  23:CLASS  24:CLASS  25:CLASS  26:CLASS  27:CLASS



L1      STRUCTURE UPLOADED

=> dis l1
L1 HAS NO ANSWERS
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sam
SAMPLE SEARCH INITIATED 09:34:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     76 TO ITERATE

100.0% PROCESSED      76 ITERATIONS                          29 ANSWERS
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           997 TO     2043
PROJECTED ANSWERS:              257 TO      903

L2            29 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 09:35:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   1538 TO ITERATE

100.0% PROCESSED    1538 ITERATIONS                          575 ANSWERS
SEARCH TIME: 00.00.01

L3           575 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               155.42     155.90

FILE 'CAPLUS' ENTERED AT 09:35:07 ON 29 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 29 Apr 2004  VOL 140 ISS 18
FILE LAST UPDATED: 28 Apr 2004  (20040428/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l3
L4            10 L3

=> s l4 and pd<march 2000
      20437244 PD<MARCH 2000
                  (PD<20000300)
L5             0 L4 AND PD<MARCH 2000

=> dis l4 1-10 bib abs

L4   ANSWER 1 OF 10  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2003:950836  CAPLUS
DN   140:16722
TI   Preparation of 1,1-disubstituted cycloalkyl derivatives as factor Xa
     inhibitors for treating a thromboembolic disorder
IN   Qiao, Jennifer X.; Pinto, Donald J.; Orwat, Michael J.; Han, Wei;
```

Friedrich, Sarah R.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 686 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003099276	A1	20031204	WO 2003-US13893	20030505

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-379357P P 20020510
US 2002-415367P P 20021002
OS MARPAT 140:16722
GI



I

AB The present application describes 1,1-disubstituted cycloalkyl compds. and derivs. thereof (P4-P-M-M4; variables defined below; most of the examples contain 1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, e.g. the trifluoroacetate of I), or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa for treatment of a thromboembolic disorder. Although the methods of preparation are not claimed, .apprx.240 example prepns. are included. A number of I exhibit Ki's of <10 μM towards factor Xa; also some I are direct acting inhibitors (Ki < 10 μM) of the serine protease thrombin as indicated by their ability to inhibit the cleavage of small mol. substrates by thrombin in a purified system; the specific compds. are not stated. For I: M is a 3-10 membered carbocycle or a 4-10 membered heterocycle, consisting of: C atoms and 1-3 heteroatoms = O, S(O)p, N, and NZ2; ring M is substituted with 0-3 R1a and 0-2 carbonyl groups, and there are 0-3 ring double bonds; P is fused onto ring M and is a 5, 6, or 7 membered carbocycle or a 5, 6, or 7 membered heterocycle, consisting of: C atoms and 1-3 heteroatoms = O, S(O)p, and N; ring P is substituted with 0-3 R1a and 0-2 carbonyl groups, and there are

0-3 ring double bonds; alternatively, ring P is absent and P4 is directly attached to ring M, provided that when ring P is absent, P4 and M4 are attached to the 1,2, 1,3, or 1,4 positions of ring M. One of P4 and M4 is -Z-A-B and the other -G1-G, provided that P4 and M4 are attached to different rings when ring P is present; G is consists of 2 fused rings D and E (ring D, including the two atoms of Ring E to which it is attached, is a 5-6 membered ring consisting of carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O)p; E is selected from (un)substituted Ph, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl; alternatively, ring D is absent and ring E is selected from (un)substituted Ph, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, thienyl, and thiazolyl); G1 is absent or = (CR3R3a)1-5, etc. A = (un)substituted C3-10 carbocycle and 5-12 membered heterocycle consisting of: C atoms and 1-4 heteroatoms N, O, and S(O)p; B is Y-R4a or X-Y-R4a, provided that Z and B are attached to different atoms on A and A and R4a or X and R4a are attached to the same atom on Y; Z = a bond, -(CR3R3e)1-4-, etc. Addnl. details including provisos are given in the claims.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:570947 CAPLUS
DN 139:133255
TI Preparation of alkylsulfonamide derivatives as acetyl CoA carboxylase (ACC) activity inhibitors for treatment of obesity, hyperlipemia, and fatty liver
IN Suzuki, Nobuyasu; Nihei, Yukio; Ichinose, Hidehiro; Hatanaka, Toshihiro; Maezono, Katsumi; Ohsumi, Koji; Kondo, Nobuo
PA Ajinomoto Co., Inc., Japan
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003059871	A1	20030724	WO 2003-JP98	20030109

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2002-2178 A 20020109
OS MARPAT 139:133255
GI



I



II

AB The title amides with general formula of I [wherein R1 = (un)substituted alkyl, alkenyl, alkynyl, aromatic hydrocarbyl, aromatic heterocyclyl, amino, alkoxy, alkenyloxy, alkynyloxy, or R2O; R2 = (un)substituted aromatic hydrocarbyl or aromatic heterocyclyl; or R1SO2 = (un)substituted aromatic (hetero)cyclyl; Y = -CR3=CR4-, -CONR3-, -NR3CO-, -N=CR3-, -CR3=N-, S, or O; R3-R6 = independently H, OH, SH, NO2, halo, CN, (un)substituted aromatic hydrocarbyl, alkyl, alkenyl, alkynyl, alkoxy, amino, or alkylthio; A = (un)substituted aromatic hydrocarbyl, aromatic heterocyclyl, cyclyl, alkenyl, nonarom. heterocyclyl, or alkylene; X = (un)substituted aromatic hydrocarbyl, heterocyclyl, cycloalkyl, or cycloalkenyl, etc.] and pharmaceutically acceptable salts thereof are prepared For example, the amide II was prepared in a multi-step synthesis. II showed IC50 of 1.00 μM against acetyl CoA carboxylase (ACC) in rat. I are useful for the treatment of obesity, hyperlipemia, and fatty liver (no data).

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:777883 CAPLUS
DN 137:294873
TI Preparation of pyridyl- and phenylbenzamides as factor Xa inhibitors for treatment of coagulation disorders
IN Zhu, Bin-Yan; Zhang, Penglie; Goldman, Erick A.; Jia, Zhaozhing Jon; Bauer, Shawn; Huang, Wenrong; Woolfrey, John; Scarborough, Robert M.
PA Millennium Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 325 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002079145	A1	20021010	WO 2002-US10523	20020401

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2003069250 A1 20030410 US 2002-115135 20020401
EP 1373194 A1 20040102 EP 2002-726698 20020401
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRAI US 2001-279696P P 20010330
WO 2002-US10523 W 20020401
OS MARPAT 137:294873
GI



I



II

AB Title compds. I [wherein Ar1-Ar3 = independently (un)substituted Ph, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or thiophenyl; L1 = direct link, (alkyl)0-2aminocarbonyl, or (alkyl)1-2amino; L2 = (alkyl)0-2aminocarbonyl or (alkyl)1-2amino; A = (un)substituted Ph, pyridinyl, imidazolyl, aminoiminomethyl, azacyclyl, guanidyl, etc.; and pharmaceutically acceptable isomers, salts, hydrates, solvates, and prodrugs thereof] were prepared For example, reaction of 2-amino-5-chloropyridine with 5-bromoisatoic anhydride in the presence of lithium bis(trimethylsilyl)amide in anhydrous THF gave 2-amino-5-bromo-N-(5-chloro-2-pyridyl)benzamide (73.6%). Treatment with Pd(PPh3)4, CuI, and (trimethylsilyl)acetylene in BuNH2 afforded the 2-amino-5-(trimethylsilylacetylenyl)benzamide derivative (91%). Amidation with 4-cyano-2-fluorobenzoic acid (94%), followed by deprotection with tert-butylammonium fluoride in THF (100%), afforded II (R = CN). The nitrile was converted to the title compound II [R = C(:NH)NMe2] by addition NHMe2 in the presence of 10% TEA/pyridine and MeI in anhydrous acetone. I have activity against mammalian factor Xa and are useful in vitro or in vivo for preventing or treating coagulation disorders (no data).
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:256253 CAPLUS

DN 136:279478
TI Preparation of quaternary amidinophenylcarboxamides as factor Xa inhibitors
IN Zhu, Bing-Yan; Huang, Wenrong; Zhang, Penglie; Jia, Zhaozhong Jon; Bao, Liang; Wu, Yanhong; Scarborough, Robert M.
PA Cor Therapeutics, Inc., USA
SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002026731	A2	20020404	WO 2001-US30314	20011001
	WO 2002026731	A3	20021003		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002011281	A5	20020408	AU 2002-11281	20011001
	EP 1322637	A2	20030702	EP 2001-979305	20011001
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004077690	A1	20040422	US 2003-381929	20031016
PRAI	US 2000-236385P	P	20000929		
	WO 2001-US30314	W	20011001		

OS MARPAT 136:279478
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; R = H, OCH3, OH, 4-morpholinyl, 1-piperidinyl, N(CH3)2, 4-tert-butoxycarbonyl-1-piperazinyl, 2-piperazinyl, HOCH2CH2N(CH3), CH3OCH2CH2N(CH3); R1 = H, Cl, OCH3, F; R2 = H, F; R4 = CH3, CH3CH2, CH3OCOCH2, HOOCCH2; R5 = CH3, HO(CH2)3, HO(CH2)2, (CH3)2N(CH2)2; A = C(N(CH3)2):N((CH3)2), Q, Q1, Q2; X = H, CH3; Y = Cl, Br], pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivs. are prepared and are having activities against mammalian factor Xa. Compns. containing title compds. I are also described. Title compds. I and the compns. are useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis.

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:256241 CAPLUS
DN 136:294843
TI Preparation of bicyclic pyrimidin-4-one based inhibitors of factor Xa
IN Zhang, Penglie; Li, Wenhao; Huang, Wenrong; Wang, Lingyan; Jia, Zhaozhong Jon; Scarborough, Robert M.; Zhu, Bing-Yan
PA Cor Therapeutics, Inc., USA
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002026718	A2	20020404	WO 2001-US30335	20011001
	WO 2002026718	A3	20020829		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	AU 2002014546	A5	20020408	AU 2002-14546	20011001
PRAI	US 2000-236331P	P	20000929		
	WO 2001-US30335	W	20011001		

OS MARPAT 136:294843
GI



I



II



III

AB The title compds. [I or II; A = C(:NH)NMe2, C(:NH)NH2, 1-methylimidazol-2-yl; Q = (un)substituted phenylene, thienylene, pyridylene; R2 = H, halo, alkoxy, etc.; R3-R7 = H, F, Cl, alkoxy, etc.; Y = CH, N; X = O, S; R = H, halo, alkyl, etc.; n = 1-5] having activity against mammalian factor Xa, and therefore useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis, were prepared E.g., a 4-step synthesis of III, starting with 2-amino-5-chloropyridine and 5-chloroisatoic anhydride, was given.

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:256235 CAPLUS
DN 136:279349
TI Preparation of novel quaternary amine containing benzamides as inhibitors of factor Xa
IN Zhang, Penglie; Zuckett, Jingmei Fan; Bao, Liang; Scarborough, Robert M.; Zhu, Bing-yan
PA Cor Therapeutics, Inc., USA
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002026712	A2	20020404	WO 2001-US42352	20011001
	WO 2002026712	A3	20021017		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002014626	A5	20020408	AU 2002-14626	20011001
	US 2004067938	A1	20040408	US 2003-381925	20031103
PRAI	US 2000-236330P	P	20000929		
	WO 2001-US42352	W	20011001		

OS MARPAT 136:279349
GI



II

AB The title compds. AQDEGJZ [I; A = R1aR1bR1cN+; R1a, R1b, R1c = alkyl, haloalkyl, cycloalkyl, etc.; Q = a direct link, CH2; D = (un)substituted phenylene, naphthylene, etc.; E = a direct link, CH2, CONH, etc.; G = (un)substituted phenylene, etc.; J = a direct link, CONH, O, etc.; Z = (un)substituted Ph, naphthyl, pyridyl, etc.] having activity against mammalian factor Xa, and useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis, were prepared Thus, reacting 4-(chloromethyl)benzoyl chloride with 4-chloro-2-(5-chloro-2-pyridyl)aminocarbonylaniline in THF (91%) followed by treatment of the resulting N-(5-chloro-2-pyridyl)-2-(4-

chloromethylphenylcarbonyl)amino-5-chlorobenzamide with Me3N in iso-Pr/H2O (68%) afforded II.

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:11104 CAPLUS
DN 136:69743
TI Preparation of pyridyl benzamides and related compounds as Factor Xa inhibitors.
IN Zhu, Bing-Yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Erick A.; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
PA USA
SO U.S. Pat. Appl. Publ., 259 pp., Cont.-in-part of U.S. Ser. No. 663,420.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002002183	A1	20020103	US 2001-794225	20010228
	US 6376515	B2	20020423		
	US 2003162690	A1	20030828	US 2002-126976	20020422
PRAI	US 2000-185746P	P	20000229		
	US 2000-663420	A2	20000915		
	US 2001-794225	A1	20010228		

OS MARPAT 136:69743
AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R2C(:NR3), (substituted) Ph, naphthyl, heterocyclyl, etc.; R1-R3 = H, OR5, NR5R6, alkyl, alkenyl, etc.; R1R2 or R2R3 = atoms to form (substituted) cycloalkyl, heterocyclyl; R5, R6 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted) alkylphenyl, alkylnaphthyl; R5R6 = atoms to form a 3-8 membered (substituted) ring; Q = bond, CH2, CO, O, S, SO, SO2, NR7, SO2NR7, etc.; R7 = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, (substituted) alkylphenyl, alkylnaphthyl; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, O, S, SO, SO2, alkylcarbonyl, etc.; G = (substituted) alkenyl, cycloalkenyl, phenylene, 3-8 membered (fused) (aromatic) heterocyclyl; J = bond, NR9CO, O, S, SO, SO2, CH2, NR9SO2, etc.; X = (substituted) Ph, naphthyl, (fused) heteroaryl], were prepared as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl)-2-aminophenylcarboxamide (preparation given), 4-cyanobenzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 70% N-(5-bromo-2-pyridinyl)-[2-(4-cyanophenylcarbonyl)amino]phenylcarboxamide. The latter in MeOH at 0° was saturated with HCl and stirred overnight followed by solvent evaporation The residue was refluxed 2 h with NH4OAc in MeOH to give 70% N-(5-bromo-2-pyridinyl)-[2-(4-amidinophenylcarbonyl)amino]phenylcarboxamide.

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:661392 CAPLUS
DN 135:226888
TI Preparation of pyridyl benzamides and related compounds as Factor Xa inhibitors.
IN Zhu, Bing-yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Erick; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
PA Cor Therapeutics, Inc., USA
SO PCT Int. Appl., 322 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064643	A2	20010907	WO 2001-US6255	20010228
	WO 2001064643	A3	20020404		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1259485	A2	20021127	EP 2001-918257	20010228
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2000-185746P	P	20000229		
	US 2000-663420	A	20000915		
	WO 2001-US6255	W	20010228		

OS MARPAT 135:226888

AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R2C(:NR3), (substituted) Ph, naphthyl, heterocyclyl, etc.; R1-R3 = H, OR5, NR5R6, alkyl, alkenyl, etc.; R1R2 or R2R3 = atoms to form (substituted) cycloalkyl, heterocyclyl; R5, R6 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted) alkylphenyl, alkylnaphthyl; R5R6 = atoms to form a 3-8 membered (substituted) ring; Q = bond, CH2, CO, O, S, SO, SO2, NR7, SO2NR7, etc.; R7 = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, (substituted) alkylphenyl, alkylnaphthyl; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, O, S, SO, SO2, alkylcarbonyl, etc.; G = (substituted) alkenyl, cycloalkenyl, phenylene, 3-8 membered (fused) (aromatic) heterocyclyl; J = bond, NR9CO, O, S, SO, SO2, CH2, NR9SO2, etc.; X = (substituted) Ph, naphthyl, (fused) heteroaryl], were prepared as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl)-2-aminophenylcarboxamide (preparation given), 4-cyanobenzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 70% N-(5-bromo-2-pyridinyl)-[2-(4-cyanophenylcarbonyl)amino]phenylcarboxamide. The latter in MeOH at 0° was saturated with HCl and stirred overnight followed by solvent evaporation The residue was refluxed 2 h with NH4OAc in MeOH to give 70% N-(5-bromo-2-pyridinyl)-[2-(4-amidinophenylcarbonyl)amino]phenylcarboxamide.

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:661391 CAPLUS

DN 135:210946

TI Preparation of pyridylamides as Factor Xa inhibitors.

IN Zhu, Bing-yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Erick; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert

PA Cor Therapeutics, Inc., USA

SO PCT Int. Appl., 306 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064642	A2	20010907	WO 2001-US6247	20010228
	WO 2001064642	A3	20020502		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				

LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-185746P P 20000229
US 2000-663420 A 20000915

OS MARPAT 135:210946

AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R1C(:NR3), (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl, etc.; R1-R3 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (alkyl)aryl, (alkyl)heteroaryl, etc.; R1R2 or R2R3 = atoms to form a 3-8 membered (substituted) (heterocyclic) ring; Q = bond, CH2, CO, O, NR7, etc.; R7 = H, alkyl, (alkyl)aryl, (alkyl)heteroaryl, etc.; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, S, SO, SO2, alkoxy, etc.; G = (substituted) alkenyl, cycloalkenyl, phenylene, heterocyclyl, fused cyclic system; J = bond, NR9CO, O, S, SO, SO2, SO2NR9, CH2, NR9, etc.; R9 = H, alkyl, (alkyl)aryl, etc.; X = (substituted) Ph, naphthyl, heteroaryl, fused bicyclyl], were prepared as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl) 2-aminophenylcarboxamide (preparation given), 4-[(2-tert-butylaminosulfonyl)phenyl]benzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 85% N-(5-bromo-2-pyridinyl)-[2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino]phenylcarboxamide.

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:208239 CAPLUS
DN 134:252153
TI Preparation of benzamides as inhibitors of factor Xa
IN Zhu, Bing-yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Eric; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
PA Cor Therapeutics, Inc., USA
SO PCT Int. Appl., 224 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019788	A2	20010322	WO 2000-US25196	20000915
	WO 2001019788	A3	20010809		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1216228	A2	20020626	EP 2000-963452	20000915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	BR 2000014076	A	20021015	BR 2000-14076	20000915
	JP 2003509406	T2	20030311	JP 2001-523368	20000915
	NO 2002001229	A	20020521	NO 2002-1229	20020312

PRAI US 1999-154332P P 19990917
US 2000-185746P P 20000229
WO 2000-US25196 W 20000915

OS MARPAT 134:252153

GI



I

AB The title compds. AQDEGJX [A = alkyl, cycloalkyl, (un)substituted Ph, etc.; Q = a direct link, CH2, CO, etc.; D = a direct link, (un)substituted Ph, naphthyl, etc.; E = a direct link, O, alkyl, etc.; G = alkenylene, cycloalkenylene, phenylene, etc.; J = a direct link, O, S, etc.; X = a (un)substituted Ph, naphthyl, heteroaryl, etc.] having activity against mammalian factor Xa (no data), and useful in vitro or in vivo for preventing or treating coagulation disorders, were prepared E.g., a 4-step synthesis of the benzamide I was given.

=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	27.66	183.56

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.93	-6.93

FILE 'CAOLD' ENTERED AT 09:35:55 ON 29 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

```
=> s l3
L6             0 L3

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.42     183.98

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -6.93

STN INTERNATIONAL LOGOFF AT 09:36:01 ON 29 APR 2004
```